1. Home
  2. VET vs MLYS Comparison

VET vs MLYS Comparison

Compare VET & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VET
  • MLYS
  • Stock Information
  • Founded
  • VET 1994
  • MLYS 2019
  • Country
  • VET Canada
  • MLYS United States
  • Employees
  • VET N/A
  • MLYS N/A
  • Industry
  • VET Oil & Gas Production
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VET Energy
  • MLYS Health Care
  • Exchange
  • VET Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • VET 961.0M
  • MLYS 890.6M
  • IPO Year
  • VET N/A
  • MLYS 2023
  • Fundamental
  • Price
  • VET $7.47
  • MLYS $12.92
  • Analyst Decision
  • VET
  • MLYS Strong Buy
  • Analyst Count
  • VET 0
  • MLYS 4
  • Target Price
  • VET N/A
  • MLYS $27.00
  • AVG Volume (30 Days)
  • VET 870.9K
  • MLYS 674.9K
  • Earning Date
  • VET 08-07-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • VET 4.58%
  • MLYS N/A
  • EPS Growth
  • VET N/A
  • MLYS N/A
  • EPS
  • VET N/A
  • MLYS N/A
  • Revenue
  • VET $1,296,504,678.00
  • MLYS N/A
  • Revenue This Year
  • VET $27.92
  • MLYS N/A
  • Revenue Next Year
  • VET N/A
  • MLYS N/A
  • P/E Ratio
  • VET N/A
  • MLYS N/A
  • Revenue Growth
  • VET 3.24
  • MLYS N/A
  • 52 Week Low
  • VET $5.14
  • MLYS $8.24
  • 52 Week High
  • VET $10.85
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • VET 42.62
  • MLYS 41.04
  • Support Level
  • VET $7.73
  • MLYS $12.83
  • Resistance Level
  • VET $8.16
  • MLYS $13.70
  • Average True Range (ATR)
  • VET 0.26
  • MLYS 0.73
  • MACD
  • VET -0.09
  • MLYS -0.09
  • Stochastic Oscillator
  • VET 3.88
  • MLYS 6.03

About VET Vermilion Energy Inc. Common (Canada)

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: